No such message found

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Q2 Zenith/Resverlogix Events
Reply New Message
Back To Forum List View
Icon president Q2 Zenith/Resverlogix Events
1
BearDownAZ
Apr 12, 2016 12:11PM
Icon president Re: Q2 Zenith/Resverlogix Events
1
SanFrancisco99
Apr 12, 2016 12:23PM
Re: Q2 Zenith/Resverlogix Events
2
Toinv
Apr 12, 2016 05:10PM
Icon president Re: Q2 Zenith/Resverlogix Events
4
SanFrancisco99
Apr 13, 2016 12:28AM
Re: Q2 Zenith/Resverlogix Events
3
Toinv
Apr 13, 2016 08:53AM
Icon president Re: Q2 Zenith/Resverlogix Events
4
BearDownAZ
Apr 17, 2016 02:11PM

AACR poster now on Zenith website. In particular, Figure 9 stated the following:

"Figure 9. Design of the phase I clinical trial of ZEN-3694 in mCRPC. In the first protocols (ZEN003694-001, NCT02705469), a dose escalation phase with ZEN-3694 as single agent will start in Q1 2016, followed by a dose expansion phase planned for Q1 2017. In the second protocol (ZEN003694-002, NCT02711956), a combination with enzalutamide dose escalation phase and expansion phase are planned for Q2 2016, and Q1 2017, respectively."

2 Recommendations
Icon president Re: Q2 Zenith/Resverlogix Events
1
SanFrancisco99
Apr 26, 2016 09:48AM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply